{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:48:36Z","timestamp":1770410916014,"version":"3.49.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urology.2025.11.238","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:27:04Z","timestamp":1763645224000},"page":"80-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Editorial Comment on \u201cClinician- and Geographic-level Variation in Utilization of Sacral Neuromodulation and OnabotulinumtoxinA Injections Among Medicare Beneficiaries With Overactive Bladder\u201d"],"prefix":"10.1016","volume":"208","author":[{"given":"Peter C.","family":"Jeppson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"Nowlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.11.238_bib1","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","author":"Cameron","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.11.238_bib2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(24)01886-5","article-title":"Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial","volume":"405","author":"Abdel-Fattah","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2025.11.238_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.11.238_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs sacral neuromodulation for refractory urgency urinary incontinence in women: a randomized clinical trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2025.11.238_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000000656","article-title":"Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial","volume":"203","author":"Harvie","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.11.238_bib6","doi-asserted-by":"crossref","unstructured":"Balk E, Adam GP, Kimmel H, et al. Nonsurgical treatments for urinary incontinence in women: a systematic review update. Agency for Healthcare Research and Quality (AHRQ); 2018. doi:10.23970\/AHRQEPCCER212.","DOI":"10.23970\/AHRQEPCCER212"},{"key":"10.1016\/j.urology.2025.11.238_bib7","unstructured":"Dreyfuss L.D., Wang L., Nik-Ahd F., et al. Clinician- and geographic-level variation in utilization of sacral neuromodulation and onabotulinumtoxinA injections among Medicare beneficiaries with overactive bladder. J Urol."},{"key":"10.1016\/j.urology.2025.11.238_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/SPV.0000000000000112","article-title":"Committee opinion: onabotulinumtoxinA and the bladder","volume":"20","year":"2014","journal-title":"Female Pelvic Med Reconstr Surg"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525013238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525013238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:05:40Z","timestamp":1770372340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525013238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":8,"alternative-id":["S0090429525013238"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.238","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial Comment on \u201cClinician- and Geographic-level Variation in Utilization of Sacral Neuromodulation and OnabotulinumtoxinA Injections Among Medicare Beneficiaries With Overactive Bladder\u201d","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}